Therapeutic Solutions International

Therapeutic Solutions International is a publicly traded biotech holding company (TSOI) with a mission to develop novel immunotherapies and regenerative medicines. Its core achievement lies in establishing a diversified portfolio of early-stage assets, primarily focused on natural killer (NK) cells and mesenchymal stem cells (MSCs), targeting cancer, neurological trauma, and inflammatory conditions. The company's strategy revolves around a capital-efficient holding structure, in-licensing promising science, and advancing programs through subsidiary entities to attract partnership capital. However, its progress is characterized by early, pre-clinical, and Phase I assets, with limited late-stage clinical validation and no commercial revenue to date.

A holding company model focused on in-licensing and developing therapies based on immunomodulatory adult stem cells (MSCs, NK cells) and exploring drug repurposing combinations, rather than a single proprietary engineering platform.

Faces intense competition from larger, better-funded biotechs in MSC therapy (e.g., Mesoblast) and NK cell oncology (e.g., Nkarta, Fate). Lacks the proprietary engineering platforms and deep clinical pipelines of these established players.